Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury

Thu Dec 11, 2008 10:01am EST

* Reuters is not responsible for the content in this press release.

VALENCIA, Calif.--(Business Wire)--
Bioness Inc., a leading neuromodulation company, announced today that beginning
January 1, 2009, the NESS L300 will be reimbursed by Medicare for incomplete
spinal cord injury patients suffering from foot drop. The decision by the
Centers for Medicare and Medicaid Services (CMS) establishes a new HCPCS code,
E0770, for functional electrical stimulation (FES) devices including the NESS
L300™ Foot Drop System. Based on this coding decision, Medicare carriers have
issued billing instructions stating formally that the NESS L300 from Bioness
will be covered for spinal cord injury patients with specific diagnosis codes
who meet certain criteria. 

Foot drop is a partial leg paralysis that prevents the foot from lifting,
causing instability and making walking difficult for persons suffering from
conditions such as incomplete spinal cord injuries, stroke, traumatic brain
injury, multiple sclerosis and cerebral palsy. The NESS L300 treats foot drop by
stimulating the muscles and nerves that lift the foot. Medicare’s decision
highlights the importance of FES and the possible improvements in an
individual’s gait, increased range-of-motion and improved blood circulation that
the NESS L300 may provide. The NESS L300 is the only adaptive, wireless
neurostimulation device for foot drop offered in acute, in-patient and
out-patient rehabilitation centers as well as for home use. 

“In the U.S. there are approximately 250,000 spinal cord injury survivors and
11,000 new spinal cord injury incidents each year,” said Evan L. Rosenfeld M.D.,
Chief Medical Officer for Bioness Inc. “This decision by CMS opens the door for
many neurologically injured patients to receive FES-based treatment. The NESS
L300 FES device may help patients regain lost mobility and increase their
overall independence, which can ultimately help them to perform everyday
activities that can greatly improve their quality of life.” 

“We are delighted with CMS’ decision to cover the NESS L300 and, more
importantly, encouraged by the impact that it will have on the lives of
thousands of people with spinal cord injuries, their caregivers and families,”
said Yitzhak Zilberman, President and CEO of Bioness Inc. “The NESS family of
products has already helped thousands of patients suffering from a variety of
neurological disorders regain mobility. We are confident that the CMS decision
will make access to the NESS L300 even easier for patients in need.” 

The NESS L300 is a prescription device used by nearly 400 in-patient and
out-patient rehabilitation facilities and select orthotic and prosthetic patient
care facilities across the United States as an adjunct to therapeutic
procedures. If a patient is determined to be appropriate for the NESS L300 in
the home, a Bioness-trained therapist configures the electrodes and trains the
patient on its proper use. Routine therapy visits are required to ensure that
the device is properly fitted and that patients receive the proper dosage levels
consistent with individual therapy goals. 

To find a Bioness-trained facility, visit the Bioness website (www.bioness.com).


Individual results vary. People should consult with a qualified physician to
determine if the NESS L300 is right for them.

About Bioness Inc.

Bioness develops, manufactures and markets innovative neuromodulation products
that aid individuals with central nervous system disorders such as stroke,
multiple sclerosis, spinal cord injury and traumatic brain injury. 

The NESS L300™ Foot Drop System and NESS H200® Hand Rehabilitation System,
cleared for use by the Food and Drug Administration and approved by the European
Union (CE Mark), are designed to enable patients to achieve new levels of
physical independence and productivity. 

Additional information about Bioness can be found at www.bioness.com. 

NESS®, NESS L300™, NESS H200®, Bioness® are trademarks of Bioness Inc. |
Manufactured by Bioness Neuromodulation Ltd., a Bioness Inc. (USA) Company,
25103 Rye Canyon Loop, Valencia, California 91355 USA | Rx Only

Use of the symbols ® and ™ herein refers to the registration status of
trademarks in the U.S. only. These trademarks may also be registered in other
countries. 





Schwartz Communications
Wendy Ryan/Thea Lavin
781-684-0770
bioness@schwartz-pr.com

Copyright Business Wire 2008

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.